Veracyte Partners with AstraZeneca Unit to Provide Genomic Data to Develop Oncology Therapeutics

Edward Kim  |

Genomics diagnostics pioneer Veracyte closed out 2019 by acquiring the exclusive global license to NanoString's nCounter platform, an FDA-cleared, automated system that can simultaneously analyze RNA, DNA or protein targets in up to 800 genes. The deal positioned Veracyte to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to physicians and their patients via hospital and clinical laboratories throughout the European Union and other parts of the world.

With the nCounter deal, Veracyte stated that the platform would enable it to access a global market worth more than $40 billion for its current and pipeline products, while expanding its margins through test menu expansion on the nCounter platform.

In its follow-up to that transaction, Veracyte announced today that it has entered into a multi-year partnership with Acerta Pharma, the hematology research and development arm of AstraZeneca, to provide genomic information to support Acerta's development of oncology therapeutics. Financial and other terms of the collaboration were not disclosed.

We are excited to partner with Acerta Pharma and AstraZeneca, global leaders whose innovative medicines are benefitting millions of patients worldwide. This collaboration reflects the significant value we can bring to biopharmaceutical companies through our expanding global footprint, as well as our ability to potentially inform diagnosis and treatment decisions in new oncology indications.

- Bonnie H. Anderson, Chairman and CEO, Veracyte.

We have been longtime followers of Veracyte and Ms. Anderson, whose career spans over 30 years in regulated diagnostics and life science markets. She co-founded Veracyte in 2008, led its IPO in 2013 and has spearheaded commercialization of the company's market-leading products.

The company reported 32% revenue growth to $31 million in the third quarter ended September 30, 2019, with 24% growth in genomic testing volume. Veracyte has reiterated full year revenue guidance of $119 million to $122 million.

Veracyte's corporate performance has been reflected in the stock price, which hit an all-time high of $31.18 this past summer. Shares are at $27.21 in mid-afternoon Wednesday trading, for a market capitalization of about $1.4 billion.

We think the company is well positioned to continue to leverage its innovations in genomic technology and machine learning to improve diagnostic accuracy while reducing risky, costly and often unnecessary surgeries.

Edward Kim is Managing Editor of Equities.com.

_____

Source: Equities News

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer. The author of this article, or a firm that employs the author, is a holder of the following securities mentioned in this article : None

Companies

Symbol Name Price Change % Volume
VCYT Veracyte Inc. 26.85 0.69 2.64 259,255 Trade
AZN Astrazeneca PLC 47.85 -1.48 -3.00 6,665,395 Trade

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

World Economic Forum at Davos 2019 - Joseph Weinberg CEO PayCase, Chairman Shyft

Matt Bird sits down with Joseph Weinberg CEO PayCase, Chairman Shyft at the World Economic Forum at Davos 2019